Prevexxion RN+HVT (--) + (--) - Concentrate and solvent for suspension for injection
Prevexxion RN+HVT (--) + (--) - Concentrate and solvent for suspension for injection
Authorised
- Marek's disease virus, serotype 1, strain RN1250, Live
- Turkey herpesvirus, strain FC-126 (cell-associated), Live
Product identification
Medicine name:
Prevexxion RN+HVT (--) + (--) - Concentrate and solvent for suspension for injection
Active substance:
- Marek's disease virus, serotype 1, strain RN1250, Live
- Turkey herpesvirus, strain FC-126 (cell-associated), Live
Target species:
-
Chicken
Route of administration:
-
Subcutaneous use
Product details
Active substance and strength:
-
Marek's disease virus, serotype 1, strain RN1250, LivePresentation_strength:2.9 - 3.9 log10 PFU Reference:Hse Index:0
-
Turkey herpesvirus, strain FC-126 (cell-associated), LivePresentation_strength:3.0 - 4.0 log10 PFU (for one single injection of 0.2 ml) Index:14
Pharmaceutical form:
-
Concentrate and solvent for suspension for injection
Withdrawal period by route of administration:
-
Subcutaneous use
-
Chicken
-
Not applicable0dayZero day
-
-
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QI01AD03
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Austria
-
Belgium
-
Bulgaria
-
Croatia
-
Cyprus
-
Czechia
-
Denmark
-
Estonia
-
Finland
-
France
-
Germany
-
Greece
-
Hungary
-
Iceland
-
Ireland
-
Italy
-
Latvia
-
Liechtenstein
-
Lithuania
-
Luxembourg
-
Malta
-
Netherlands
-
Norway
-
Poland
-
Portugal
-
Romania
-
Slovakia
-
Slovenia
-
Spain
-
Sweden
-
United Kingdom (Northern Ireland)
Package description:
- Packaging:ampoule (glass), Package_size:1 ampoule, Content:4000 doses
- Packaging:ampoule (glass), Package_size:1 ampoule, Content:2000 doses
- Packaging:ampoule (glass), Package_size:1 ampoule, Content:1000 doses
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Combination veterinary medicinal products (Article 20 of Regulation (EU) 2019/6)
Marketing authorisation holder:
- Boehringer Ingelheim Vetmedica GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
- Boehringer Ingelheim Animal Health France
- LABORATOIRE BIOLUZ
- LABORATOIRE BIOLUZ
- Boehringer Ingelheim Animal Health France
- LABORATOIRE BIOLUZ
- Boehringer Ingelheim Animal Health France
- LABORATOIRE BIOLUZ
- Boehringer Ingelheim Animal Health France
Responsible authority:
- European Commission
Authorisation number:
This information is not available for this product.
Date of authorisation status change:
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Combined File of all Documents
English (PDF)
Download Published on: 5/03/2025
Bulgarian (PDF)
Published on: 5/03/2025
Croatian (PDF)
Published on: 5/03/2025
Czech (PDF)
Published on: 5/03/2025
Danish (PDF)
Published on: 5/03/2025
Dutch (PDF)
Published on: 5/03/2025
Estonian (PDF)
Published on: 5/03/2025
Finnish (PDF)
Published on: 5/03/2025
French (PDF)
Published on: 5/03/2025
German (PDF)
Published on: 5/03/2025
Greek (PDF)
Published on: 5/03/2025
Hungarian (PDF)
Published on: 5/03/2025
Icelandic (PDF)
Published on: 5/03/2025
Italian (PDF)
Published on: 5/03/2025
Latvian (PDF)
Published on: 5/03/2025
Lithuanian (PDF)
Published on: 5/03/2025
Maltese (PDF)
Published on: 5/03/2025
Norwegian (PDF)
Published on: 5/03/2025
Polish (PDF)
Published on: 5/03/2025
Portuguese (PDF)
Published on: 5/03/2025
Romanian (PDF)
Published on: 5/03/2025
Slovak (PDF)
Published on: 5/03/2025
Slovenian (PDF)
Published on: 5/03/2025
Spanish (PDF)
Published on: 5/03/2025
Swedish (PDF)
Published on: 5/03/2025
ema-puar-v6146-prevexxion-rn-hvt-en.pdf
English (PDF)
Download Published on: 23/12/2023
How useful was this page?:
